Cinco maneiras pelas quais pacientes imunocomprometidos podem se proteger da COVID-19

Conforme as famílias se reúnem para as festas de final de ano, é importante que os pacientes imunocomprometidos tomem medidas extras para ajudar a se proteger da COVID-19. Pessoas com o sistema imunológico enfraquecido correm maior risco de adoecer gravemente com a COVID-19.

New Study Suggests Healthcare Provider Biases Can Impact a Patient’s Access to Preventative HIV Drug

A new study published today reveals systematic biases among primary and HIV care providers about people who inject drugs and how those biases may impact access to pre-exposure prophylaxis (PrEP), a preventive, prescription-based medication that significantly reduces the risk of HIV infection through sexual behavior and injection practices.

IHV Researchers Receive $6.5M to Create African Big Data Hub Designed to Address Public Health and Pandemic Preparedness

Researchers at the University of Maryland School of Medicine (UMSOM)’s Institute of Human Virology (IHV), a Global Virus Network (GVN) Center of Excellence, have received $6.5 million from the U.S. National Institutes of Health (NIH) to streamline big data collection in Nigeria and South Africa in addressing public health needs of the COVID-19 and HIV pandemics.

Virtual Village Treats HIV-associated Loneliness in Novel UC San Diego Health Trial

A new trial by UC San Diego Health infectious disease specialist Maile Young Karris, MD, will use longitudinal questionnaires and qualitative interviews to assess the impact of living in an interconnected virtual village on the loneliness known to afflict older people with HIV.

Einstein-Developed Treatment Strategy May Lead to HIV Cure

Armed with a novel strategy they developed for bolstering the body’s immune response, scientists at Albert Einstein College of Medicine have successfully suppressed HIV infections in mice—offering a path to a functional cure for HIV and other chronic viral infections. Their findings were published today in the Journal of Clinical Investigation.

Albert Einstein College of Medicine and City University of New York Researchers Receive $14.5 Million NIH Grant to Lead HIV Studies in Central Africa

Researchers at Albert Einstein College of Medicine and the City University of New York Graduate School of Public Health and Health Policy (CUNYSPH) have been awarded a five-year, $14.5 million grant from the National Institutes of Health (NIH) to continue leading and expand their research on HIV treatment and care in five Central African nations.

BIDMC researchers awarded $24.5 million by NIH to find a cure for HIV

A team led by Dan H. Barouch, MD, PhD, has been awarded $4.9 million in annual funding over the next five years to find a cure for HIV. Barouch was one of ten primary investigators to receive a 2021 National Institutes of Health (NIH) Martin Delaney Collaboratories for HIV Cure Research award, which aims to expedite human immunodeficiency virus (HIV) cure research by bringing together research partners in academia, government, the private sector and the community; coordinating complex research studies, and mentoring the next generation of HIV cure researchers.

Hopkins Med News Update

NEWS STORIES IN THIS ISSUE:

– COVID-19 NEWS: Johns Hopkins Medicine Study Shows Vaccine Likely Protects People with HIV
– Johns Hopkins Medicine Documents Stroke Risk in Cardiac Assist Device
– CBD Products May Help People with Epilepsy Better Tolerate Anti-Seizure Medications

Dr. Chandra Ford – Founding Director, Center for the Study of Racism, Social Justice & Health, Professor of Community Health Sciences, UCLA Fielding School of Public Health, available as expert on health equity

Dr. Chandra Ford, founding director of the Center for the Study of Racism, Social Justice & Health and professor of Community Health Sciences, UCLA Fielding School of Public Health, is available as expert on health equity. Prof. Ford’s expertise includes:…

UM School Of Medicine Researchers Receive NIH Avant Garde Award For Out-Of-Box, Innovative Concept To Cure HIV And Treat Co-Existing Addiction

University of Maryland School of Medicine (UMSOM) Professor of Diagnostic Radiology & Nuclear Medicine, Linda Chang, MD, MS, received the National Institute on Drug Abuse (NIDA) 2021 Avant Garde Award (DP1) for HIV/AIDS and Substance Use Disorder Research — a National Institutes of Health (NIH) Director’s Pioneer Award.

Wistar Scientists Discover Blood-based Biomarkers to Predict HIV Remission After Stopping Antiretroviral Therapy

New biomarkers that predict HIV remission after antiretroviral therapy (ART) interruption are critical for the development of new therapeutic strategies that can achieve infection control without ART, a condition defined as functional cure. Wistar Scientists have identified metabolic and glycomic signatures in the blood of a rare population of HIV-infected individuals who can naturally sustain viral suppression after ART cessation, known as post-treatment controllers. T

Forty years of nursing science in HIV/AIDS: JANAC marks progress and challenges

From the very beginning of the AIDS epidemic in 1981, nurses have been at the forefront of patient care, advocacy, and research. But even in the age of antiretroviral therapy and pre-exposure prophylaxis, many challenges remain in reducing the impact of HIV and AIDS, according to the special May/June issue of The Journal of the Association of Nurses in AIDS Care (JANAC). The official journal of the Association of Nurses in AIDS Care, JANAC is published in the Lippincott portfolio by Wolters Kluwer.

People at High Risk for HIV Know about Prevention Pill, But Use Remains Low

Cisgender sexual minority men and transgender women are aware of pre-exposure prophylaxis (PrEP), a daily pill for HIV-negative people to prevent HIV infection, but few are currently taking it, according to researchers at Rutgers.
The study, published in the journal AIDS and Behavior, surveyed 202 young sexual minority men and transgender women – two high-priority populations for HIV prevention – to better understand why some were more likely than others to be taking PrEP.

Laurie Garrett, Pulitzer Prize-Winning Journalist, Named 2021 Senator Frank R. Lautenberg Award Recipient by the Rutgers School of Public Health

Laurie Garrett, a Pulitzer-Prize-winning journalist, has been named the 2021 Senator Frank R. Lautenberg Awardee by the Rutgers School of Public Health. She will serve as the School’s speaker at their 38th graduation ceremony, which will virtually launch on May 14, 2021.

Tip Sheet: New COVID-19 transmission study, returning to school, video of biorepositories — and a new weight loss study

SEATTLE —  April 2, 2021 — Below are summaries of recent Fred Hutch research findings and other news. April is National Minority Health Month, with a focus on the disproportionate impacts of COVID-19 on communities of color. See more details below on related Fred Hutch programming.Save the date for our monthly public science event, “Science Says” on Tuesday, April 27.

Robert Gallo, Co-Discoverer of HIV, Delivers Prestigious Uniformed Services University Packard Award Lecture

Dr. Robert C. Gallo, the Homer and Martha Gudelsky Distinguished Professor in Medicine, director and co-founder of the Institute of Human Virology (IHV) at the University of Maryland School of Medicine, and the co-Founder and International Scientific Advisor of the Global Virus Network, presented “From T Cells and Human Retroviruses to the SARS-CoV-2 Pandemic and Innate Immunity” as the 2021 David Packard Award Lecturer at the Uniformed Services University of the Health Sciences (USU), Monday, March 22.

Study Finds Low Awareness of PrEP, the Highly Effective Medication that Protects Individuals from HIV

A study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that just under 20 percent of HIV-uninfected patients visiting Baltimore sexual health clinics were aware of pre-exposure prophylaxis medication (PrEP), a daily regimen that decreases a person’s risk of contracting HIV from sex by more than 90 percent.

Harnessing the Power of Proteins in our Cells to Combat Disease

A lab on UNLV’s campus has been a hub of activity in recent years, playing a significant role in a new realm of drug discovery — one that could potentially provide a solution for patients who have run out of options.

The US Must Address the Rising Rates of HIV infections among Latinx Sexual and Gender Minorities, Says New Analysis

In 2019, the U.S. rolled out a new initiative aimed at ending the HIV epidemic by the year 2030. In a new analysis published in The Lancet, Carlos Rodriguez-Diaz, an Associate Professor at the George Washington University, suggests that initiative will fail unless the U.S. addresses the rising rates of HIV infection in Latinx sexual and gender minority populations.

Vanderbilt, Zambia Researchers Find Delirium in Hospitalized Patients Linked to Mortality, Disability in Sub-Saharan Africa

Delirium, a form of acute brain dysfunction, is widespread in critically ill patients in lower resourced hospitals, and the duration of delirium predicted both mortality and disability at six months after discharge, according to a study published in PLOS ONE.

Human immune cells have natural alarm system against HIV

Researchers at Washington University School of Medicine in St. Louis have identified a potential way to eradicate the latent HIV infection that lies dormant inside infected immune cells. Studying human immune cells, the researchers showed that such cells have a natural alarm system that detects the activity of a specific HIV protein. Rather than attack the virus based on appearance, this strategy is to attack the virus based on what it is doing — vital activities that are required for the virus to exist.

Research finds people diagnosed with HIV in New York State were more than twice as likely to die from COVID-19

New research out of the University at Albany and the AIDS Institute at the New York State Department of Health found that through the middle of 2020, people diagnosed with HIV infection were significantly more likely to contract, be hospitalized with and die from COVID-19.

Scientists at Texas Biomed aim to test therapeutic effects of CBD/THC against HIV-induced neurological disorder

The National Institutes of Health (NIH) awarded Professor Mahesh Mohan, D.V.M., Ph.D., and collaborators more than $3.5 million over five years to investigate the effects of cannabinoids on Human Immunodeficiency Virus (HIV) associated neurocognitive disorder (HAND). This research project aims to evaluate whether delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) alone or in combination can potentially alter DNA methylation, which is a biological process that can create a change in the expression of certain genes.

Tip Sheet: Celebrate holidays safely, COVID-19 vaccines, challenges in HIV vaccine trials — and new insights on evolution

SEATTLE – Dec. 2, 2020 – Below are summaries of recent Fred Hutch research findings and other news with links for additional background and media contacts.If you’re following the American Society of Hematology’s annual meeting (virtual, Dec. 5-8), see our media tip sheet highlighting Fred Hutch presentations and activities, including those by current ASH president Dr.